CLDX Sep 2024 60.000 call
| Previous close | 1.9700 |
| Open | 1.9700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 60.00 |
| Expiry date | 2024-09-20 |
| Day's range | 1.9700 - 1.9700 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GuruFocus.comInsider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...
On June 7, 2024, Diane Young, Senior Vice President and Chief Medical Officer of Celldex Therapeutics Inc (NASDAQ:CLDX), sold 45,000 shares of the company.
GlobeNewswireCelldex Therapeutics to Present at Jefferies Healthcare Conference
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage b
- GlobeNewswire
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data further support barzolvolimab clinical benefit to patients with CSU - HAMPTON, N.J., June 02, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in c
